Thymidine Phosphorylase Inhibitors: Recent Developments and Potential Therapeutic Applications

Author(s): Maria-Jesus Perez-Perez , Eva-Maria Priego , Ana-Isabel Hernandez , Maria-Jose Camarasa , Jan Balzarini , Sandra Liekens .

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 5 , Issue 12 , 2005

Become EABM
Become Reviewer

Abstract:

Thymidine Phosphorylase (TPase) catalyses the reversible phosphorolysis of pyrimidine 2- deoxynucleosides to 2-deoxyribose-1-phosphate and their respective pyrimidine bases, including the phosphorolysis of nucleoside analogues with important antiviral or anticancer properties. Moreover, TPase, identified also as the angiogenic platelet-derived endothelial cell growth factor (PD-ECGF), stimulates endothelial cell migration in vitro and angiogenesis in vivo and plays an important role in tumour progression and metastasis. Here we have summarized the most recent approaches in the search for novel TPase inhibitors together with the potential therapeutic applications of such inhibitors.

Keywords: Thymidine Phosphorylase, PD-ECGF, angiogenesis, nucleoside metabolism, anticancer drugs, Thymidine Phosphorylase Inhibitors, Inhibitor Design

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 5
ISSUE: 12
Year: 2005
Page: [1113 - 1123]
Pages: 11
DOI: 10.2174/138955705774933301
Price: $58

Article Metrics

PDF: 22